Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma

Abstract Background Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection. In case of anaplastic meningiomas (WHO grade III), adjuvant fractionated radiotherapy is generally recommende...

Full description

Bibliographic Details
Main Authors: Saman Moritz Hemmati, Pirus Ghadjar, Arne Grün, Harun Badakhshi, Sebastian Zschaeck, Carolin Senger, Güliz Acker, Martin Misch, Volker Budach, David Kaul
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Radiation Oncology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13014-019-1368-z
id doaj-d2f0bdddf4d44549b6b10b16d0830ce7
record_format Article
spelling doaj-d2f0bdddf4d44549b6b10b16d0830ce72020-11-25T03:10:44ZengBMCRadiation Oncology1748-717X2019-09-011411710.1186/s13014-019-1368-zAdjuvant radiotherapy improves progression-free survival in intracranial atypical meningiomaSaman Moritz Hemmati0Pirus Ghadjar1Arne Grün2Harun Badakhshi3Sebastian Zschaeck4Carolin Senger5Güliz Acker6Martin Misch7Volker Budach8David Kaul9Department of Radiation Oncology, Charité Universitätsmedizin BerlinDepartment of Radiation Oncology, Charité Universitätsmedizin BerlinDepartment of Radiation Oncology, Charité Universitätsmedizin BerlinDepartment of Radiation Oncology, Ernst von Bergmann Medical CenterDepartment of Radiation Oncology, Charité Universitätsmedizin BerlinDepartment of Radiation Oncology, Charité Universitätsmedizin BerlinDepartment of Neurosurgery, Charité Universitätsmedizin BerlinDepartment of Neurosurgery, Charité Universitätsmedizin BerlinDepartment of Radiation Oncology, Charité Universitätsmedizin BerlinDepartment of Radiation Oncology, Charité Universitätsmedizin BerlinAbstract Background Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection. In case of anaplastic meningiomas (WHO grade III), adjuvant fractionated radiotherapy is generally recommended, regardless of the extent of surgical resection. For atypical meningiomas (WHO grade II) optimal postoperative management has not been clearly defined yet. Methods We conducted a retrospective analysis of patients treated for intracranial atypical meningioma at Charité Universitätsmedizin Berlin from March 1999 to October 2018. Considering the individual circumstances (risk of recurrence, anatomical location, etc.), patients were either advised to follow a wait-and-see approach or to undergo adjuvant radiotherapy. Primary endpoint was progression-free survival (PFS). Results This analysis included 99 patients with atypical meningioma (WHO grade II). Nineteen patients received adjuvant RT after primary tumor resection (intervention group). The remaining 80 patients did not receive any further adjuvant therapy after surgical resection (control group). Median follow-up was 37 months. Median PFS after primary resection was significantly longer in the intervention group than in the control group (64 m vs. 37 m, p = 0.009, HR = 0.204, 95% CI = 0.062–0.668). The influence of adjuvant RT was confirmed in multivariable analysis (p = 0.041, HR = 0.192, 95% CI = 0.039–0.932). Conclusions Our study adds to the evidence that RT can improve PFS in patients with atypical meningioma.http://link.springer.com/article/10.1186/s13014-019-1368-zAtypical meningiomaAdjuvant radiotherapyFractionated stereotactic radiotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Saman Moritz Hemmati
Pirus Ghadjar
Arne Grün
Harun Badakhshi
Sebastian Zschaeck
Carolin Senger
Güliz Acker
Martin Misch
Volker Budach
David Kaul
spellingShingle Saman Moritz Hemmati
Pirus Ghadjar
Arne Grün
Harun Badakhshi
Sebastian Zschaeck
Carolin Senger
Güliz Acker
Martin Misch
Volker Budach
David Kaul
Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
Radiation Oncology
Atypical meningioma
Adjuvant radiotherapy
Fractionated stereotactic radiotherapy
author_facet Saman Moritz Hemmati
Pirus Ghadjar
Arne Grün
Harun Badakhshi
Sebastian Zschaeck
Carolin Senger
Güliz Acker
Martin Misch
Volker Budach
David Kaul
author_sort Saman Moritz Hemmati
title Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
title_short Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
title_full Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
title_fullStr Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
title_full_unstemmed Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
title_sort adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
publisher BMC
series Radiation Oncology
issn 1748-717X
publishDate 2019-09-01
description Abstract Background Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection. In case of anaplastic meningiomas (WHO grade III), adjuvant fractionated radiotherapy is generally recommended, regardless of the extent of surgical resection. For atypical meningiomas (WHO grade II) optimal postoperative management has not been clearly defined yet. Methods We conducted a retrospective analysis of patients treated for intracranial atypical meningioma at Charité Universitätsmedizin Berlin from March 1999 to October 2018. Considering the individual circumstances (risk of recurrence, anatomical location, etc.), patients were either advised to follow a wait-and-see approach or to undergo adjuvant radiotherapy. Primary endpoint was progression-free survival (PFS). Results This analysis included 99 patients with atypical meningioma (WHO grade II). Nineteen patients received adjuvant RT after primary tumor resection (intervention group). The remaining 80 patients did not receive any further adjuvant therapy after surgical resection (control group). Median follow-up was 37 months. Median PFS after primary resection was significantly longer in the intervention group than in the control group (64 m vs. 37 m, p = 0.009, HR = 0.204, 95% CI = 0.062–0.668). The influence of adjuvant RT was confirmed in multivariable analysis (p = 0.041, HR = 0.192, 95% CI = 0.039–0.932). Conclusions Our study adds to the evidence that RT can improve PFS in patients with atypical meningioma.
topic Atypical meningioma
Adjuvant radiotherapy
Fractionated stereotactic radiotherapy
url http://link.springer.com/article/10.1186/s13014-019-1368-z
work_keys_str_mv AT samanmoritzhemmati adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT pirusghadjar adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT arnegrun adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT harunbadakhshi adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT sebastianzschaeck adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT carolinsenger adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT gulizacker adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT martinmisch adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT volkerbudach adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
AT davidkaul adjuvantradiotherapyimprovesprogressionfreesurvivalinintracranialatypicalmeningioma
_version_ 1724657661130047488